Compounds | Topics | Title | Date |
---|---|---|---|
CBD | opioid,heroin,addiction in humans via placebo trial | Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial | May 2019 |
Ingestion Method: oral 400-800mg Positive Acute CBD administration, in contrast to placebo, significantly reduced both craving and anxiety induced by the presentation of salient drug cues compared with neutral cues. CBD also showed significant protracted effects on these measures 7 days after the final short-term (3-day) CBD exposure. In addition, CBD reduced the drug cue-induced physiological measures of heart rate and salivary cortisol levels. There were no significant effects on cognition, and there were no serious adverse effects. | |||
cannabis | opioid via model | THE EFFECTS OF RECREATIONAL MARIJUANA LEGALIZATION AND DISPENSING ON OPIOID MORTALITY | Aug 2019 |
In our preferred econometric specification, we estimate that RMLs reduce annual opioid mortality in the range of 20%-35%, with particularly pronounced effects for synthetic opioids. | |||
THC | addiction,opioid in rats | Low dose combination of morphine and delta-9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors | Oct 2008 |
Administration of THC attenuated cannabinoid CB1 receptor-stimulated G-protein activity in both periaqueductal gray and spinal cord, and administration of morphine decreased mu opioid receptor-stimulated [35S]GTPgS binding in spinal cord or periaqueductal gray, depending on route of administration | |||
WIN55 | opioid in rats via experiment (n=30) | Differential effect of opioid and cannabinoid receptor blockade on heroin-seeking reinstatement and cannabinoid substitution in heroin-abstinent rats | Apr 2011 |
Ingestion Method: intravenous Action Pathway: CB1,opioid Neutral Our findings extend previous research on the crosstalk between cannabinoid and opioid receptors in relapse mechanisms, which suggests a differential role in heroin-seeking reinstatement and cannabinoid substitution in heroin-abstinent rats. | |||
cannabinoids | opioid via review | Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies | Feb 2015 |
Both opioid and cannabinoid receptors are coupled to G proteins and are expressed throughout the brain reinforcement circuitry. Extending classical pharmacology, research using genetically modified mice has provided important progress in the identification of the specific contribution of each component of these endogenous systems in vivo on reward process. | |||
CBD | opioid via review | Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage | Aug 2015 |
Our paper provides an overview of preclinical animal and human clinical investigations, and presents preliminary clinical data that collectively sets a strong foundation in support of the further exploration of CBD as a therapeutic intervention against opioid relapse. | |||
cannabis | addiction,opioid via review | Emerging Evidence for Cannabis' Role in Opioid Use Disorder | Sept 2018 |
The compelling nature of these data and the relative safety profile of cannabis warrant further exploration of cannabis as an adjunct or alternative treatment for OUD. | |||
CBD | addiction,opioid,methamphetamine via review | Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms | Jun 2019 |
In the present work, the authors describe the scarce preclinical and human research about the actions of CBD on the effects of stimulant drugs, mainly cocaine and methamphetamine (METH). Additionally, the possible mechanisms underlying the therapeutic potential of CBD on stimulant use disorders are reviewed. | |||
THC | addiction,opioid in rats via experiment | Attenuation of precipitated abstinence in methadone-dependent rats by delta 9-THC | Jan 1975 |
Abstinence scores in animals pretreated acutely with 10 mg/kg delta 9-THC one hour before naloxone were significantly less than those of a vehicle control group, and wet shakes and gastrointestinal signs of abstinence were blocked. These results extend previous observations of morphine abstinence attenuating properties of delta 9-THC to effects on animals dependent on methadone. | |||
THC | addiction,opioid via review | Endocannabinoid system and opioid addiction: behavioural aspects. | Jun 2005 |
The current review examines progresses in the past few years in the elucidation of cannabinoid-opioid interactions in drug abuse and dependence, focusing on recent findings from behavioural studies using different animal models of addiction. Specifically, here we review data on the behavioural aspects (i.e., drug abuse, dependence, tolerance, sensitization, relapse and drug vulnerability) of the specific, often reciprocal, cross-talk between cannabinoids and opioids with particular reference to the role of the endocannabinoid system in opioid addiction. | |||
AM251 | opioid in rats via experiment (n=122) | Cannabinoid CB1 receptors mediate the effects of corticotropin-releasing factor on the reinstatement of cocaine seeking and expression of cocaine-induced behavioural sensitization | Apr 2012 |
Ingestion Method: intravenous Action Pathway: CRF,CB1 The CB1 receptor antagonist, AM251, blocked CRF-induced reinstatement of cocaine seeking but was without effect on footshock- or cocaine-induced reinstatement of cocaine seeking | |||
cannabis | elderly,opioid in humans via survey (n=2736) | Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. | Mar 2018 |
Positive Our study finds that the therapeutic use of cannabis is safe and efficacious in the elderly population. Cannabis use may decrease the use of other prescription medicines, including opioids | |||
cannabis | addiction,opioid in humans via study (n=820) | High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis | Dec 2018 |
Among people who use illicit drugs initiating opioid agonist treatment in Vancouver, at least daily cannabis use was associated with approximately 21% greater odds of retention in treatment compared with less than daily consumption. | |||
cannabis | opioid in humans via review (n=4840562) | Impact of Medical Marijuana Legalization on Opioid Use, Chronic Opioid Use, and High-risk Opioid Use. | Jan 2019 |
Positive Medical marijuana legalization was found to be associated with a lower odds of any opioid use: OR = 0.95 (0.94-0.96), chronic opioid use: OR = 0.93 (0.91-0.95), and high-risk opioid use: OR = 0.96 (0.94-0.98) | |||
THC | opioid in rats via experiment | delta-9-tetrahydrocannabinol attenuates oxycodone self-administration under extended access conditions. | Jun 2019 |
Ingestion Method: 0.15 mg/kg/infusion and 0-10 mg/kg, i.p. Fewer oxycodone infusions were obtained by rats following vaporized or injected THC compared with vehicle treatment prior to the session. Follow-up studies demonstrated parallel dose-dependent effects of THC, i.p., on self-administration of different per-infusion doses of oxycodone and a preserved loading dose early in the session. | |||
cannabis | pain,opioid in humans via survey (n=77) | Medical Cannabis: Effects on Opioid and Benzodiazepine Requirements for Pain Control. | May 2019 |
Positive Over the course of this 6-month retrospective study, patients using medical cannabis for intractable pain experienced a significant reduction in the number of MMEs available to use for pain control. |